Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation by Hong, Soyon et al.




Dynamic analysis of amyloid β-protein in behaving
mice reveals opposing changes in ISF versus












See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Hong, Soyon; Quintero-Monzon, Omar; Ostaszewski, Beth L.; Podlisny, Daniel R.; Cavanaugh, William T.; Yang, Ting; Holtzman,
David M.; Cirrito, John R.; and Selkoe, Dennis J., ,"Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes
in ISF versus parenchymal Aβ during age-related plaque formation." Journal of Neuroscience.31,44. 15861-15869. (2011).
http://digitalcommons.wustl.edu/open_access_pubs/683
Authors
Soyon Hong, Omar Quintero-Monzon, Beth L. Ostaszewski, Daniel R. Podlisny, William T. Cavanaugh, Ting
Yang, David M. Holtzman, John R. Cirrito, and Dennis J. Selkoe
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/683
Neurobiology of Disease
Dynamic Analysis of Amyloid -Protein in Behaving Mice
Reveals Opposing Changes in ISF versus Parenchymal A
during Age-Related Plaque Formation
Soyon Hong,1 Omar Quintero-Monzon,1 Beth L. Ostaszewski,1Daniel R. Podlisny,1William T. Cavanaugh,1 Ting Yang,1
David M. Holtzman,2 John R. Cirrito,2 and Dennis J. Selkoe1
1Center for Neurologic Diseases, Brigham andWomen’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, and 2Department of
Neurology, Developmental Biology, Hope Center for Neurological Disorders, Alzheimer’s Disease Research Center, Washington University School of
Medicine, St. Louis, Missouri 63110
Growing evidence supports the hypothesis that soluble, diffusible forms of the amyloid-peptide (A) are pathogenically important in
Alzheimer’s disease (AD) and thus have both diagnostic and therapeutic salience. To learn more about the dynamics of soluble A
economy in vivo, we usedmicrodialysis to sample the brain interstitial fluid (ISF), which contains themost soluble A species in brain at
steady state, in40 wake, behaving APP transgenic mice before and during the process of A plaque formation (age 3–28 months).
Diffusible forms of A, especially A42 , declined significantly in ISF as mice underwent progressive parenchymal deposition of A.
Moreover, radiolabeled A administered at physiological concentrations into ISF revealed a striking difference in the fate of soluble A
in plaque-rich (vs plaque-free) mice: it clears more rapidly from the ISF and becomes more associated with the TBS-extractable pool,
suggesting that cerebral amyloid deposits can rapidly sequester soluble A from the ISF. Likewise, acute -secretase inhibition in
plaque-freemice showed amarked decline of A38 , A40 , andA42 , whereas in plaque-richmice, A42 declined significantly less. These
results suggest thatmost of the A42 that populates the ISF in plaque-richmice is derived not fromnewA biosynthesis but rather from
the large reservoir of less soluble A42 in brain parenchyma. Together, these and other findings herein illuminate the in vivo dynamics of
soluble A during the development of AD-type neuropathology and after -secretase inhibition and help explain the apparent paradox
that CSF A42 levels fall as humans develop AD.
Introduction
After decades of investigative focus on amyloid plaques in Alzhei-
mer’s disease (AD), recent findings have led to a conceptual shift.
Emerging evidence suggests that the insoluble amyloid fibrils that
comprise plaques may not directly confer neurotoxicity but se-
quester small, diffusible assemblies of amyloid -peptide (A)
that have been shown to potently alter synaptic structure and
function (Walsh and Selkoe, 2007). The recognition of A oli-
gomers as highly bioactive assemblies has furthered interest in
detecting and analyzing soluble forms of the peptide for mecha-
nistic, diagnostic, and therapeutic purposes. Although factors
other than A dyshomeostasis contribute importantly to the
pathogenesis of AD (Pimplikar et al., 2010), virtually all poten-
tially disease-modifying treatments currently under develop-
ment are focused on decreasing or neutralizing this neurotoxic
peptide. Moreover, a reduced CSF level of A42 in subjects with
incipient or very early AD is one of themost promising biomark-
ers. Despite this therapeutic and diagnostic focus, we still lack
insight into the in vivo economy of the most soluble forms of A
in the brain during the development of AD-type pathology.
Here, we used brain microdialysis in awake and behaving
hAPP transgenic (tg) mice to gain an understanding of A dy-
namics before and during the process of A plaque formation.
Brain interstitial fluid (ISF) contains theA pool that best reflects
the physiological secretion and fate of soluble species. Microdi-
alysis in mouse models of AD and even human subjects is pro-
viding important insights into the dynamics of normal ISF A
economy (Brody et al., 2008; Cirrito et al., 2008; Kang et al., 2009)
and may help identify the earliest, most subtle A changes that
occur as AD-type neuropathology begins. Given the power of this
in vivo sampling method, we performed hippocampal microdi-
alysis on 40 freely moving APP transgenic mice of increasing
age as a model of cerebral A accumulation, and we searched for
changes in the quality and quantity of A species as the brain
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accrues insoluble deposits and undergoes neuronal and glial in-
jury. We systematically analyzed the nature of endogenous A
over time using sensitive sandwich ELISAs, immunoprecipita-
tion (IP)/Western blotting (WB), native and denaturing PAGE,
and size exclusion chromatography (SEC). We then comple-
mented these analyses by assessing the fate of radiolabeled A
microinjected at physiological concentrations as a surrogate of
newly secreted A, and the results help explain the fall of A42 in
the CSF of humans with AD. Together, these experiments de-
scribe the in vivo dynamics of the most soluble pool of brain A
during the process of AD-type amyloid plaque formation.
Materials andMethods
Mice. J20 line carrying hAPP minigene with FAD mutations KM670/
671NL and V717F (a kind gift from L. Mucke, Gladstone Institute, Uni-
versity of California San Francisco, San Francisco, CA) was maintained
on a C57BL6  DBA2 background (Mucke et al., 2000). All animal
procedures were approved by the Harvard Medical School Institutional
Animal Care and Use Committee. Mice of both sexes were used in all
experiments.
In vivo A microdialysis. Microdialysis was performed as previously
described (Cirrito et al., 2003): intracerebral guides were inserted follow-
ing the coordinates for left hippocampal placement (bregma:3.1 mm,
2.5 mm lateral to midline, and 1.2 mm below dura at 12° angle). Perfu-
sion buffer [1.5% bovine serum albumin in artificial CSF (in mM: 1.3
CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3, and 122 NaCl, pH
7.35)] was perfused using probes with 35 kDa molecular weight cutoff
(MWCO) membranes (BR-2; Bioanalytical Systems) at flow rates 0.2–1
l/min with an infusion syringe pump (Stoelting). Microdialysates (ISF)
were collected using a refrigerated fraction collector (Univentor). Mice
were kept on 12 h light/dark cycles, and housed in a Raturn cage system
(Bioanalytical Systems), which allowedmice to resume normal activities.
Interpolated zero-flow method. The in vivo percentage recovery was
calculated as previously described (Cirrito et al., 2003). ISF was collected
from 3- and 24-month-old tg mice while varying the perfusion rates
(PR): 1.0, 0.8, 0.6, 0.4, and 0.2l/min. A levels weremeasured using the
6E10 A Triplex ELISA (MesoScale Discovery) and the values obtained
at each PRwere plotted versus the respective PR. The 100% recovery (i.e.,
the theoretical maximal amount of exchangeable ISF A species occur-
ring at a zero PR) was calculated by extrapolating back the curve to a
zero-flow rate. Then, for each PR, percentage recovery was determined
by calculating howmuch%Awas captured compared with the theoret-
ical [A] at zero PR.
A ELISA. For 6E10 A Triplex ELISA, we used the MSD 96-well
MULTI-SPOT Human (6E10) A Triplex Assay (MesoScale Discovery)
following the manufacturer’s protocol. Briefly, ISF samples were loaded
in duplicates onto MULTI-SPOTmicroplates precoated with antibodies
specific to the C termini of A38, A40, and A42 and detected with
SULFO-TAG-labeled 6E10 antibody. Light emitted upon electrochemi-
cal stimulation was read using the SECTOR Imager 2400A. For A(1–x)
ELISA, we followed a previously described protocol (Townsend et al.,
2011). Nunc MaxiSorp 96-well plates were used with 4G8 (to A17–24;
Covance) as capture and biotinylated 82E1 (to A1–16, IBL) as detection
antibodies. Signals were amplified with AttoPhos (Promega) and mea-
sured by Victor2 fluorescent plate reader (PerkinElmer).
Lactate, pyruvate, and glycerol measurements. Levels were measured
from ISF sampled at 0.2 l/min using the CMA600 analyzer at the Yale
Center forClinical Investigation (sensitivitieswere as follows: lactate 0.02
mM, pyruvate 2 M, and glycerol 2 M).
Mouse brain sample preparation for biochemical analyses. Brains were
homogenized using a mechanical Dounce homogenizer with 20 strokes
at 4000 rpm in ice-cold TBS (20mMTris-HCl, 150mMNaCl, pH 7.4) and
protease inhibitors at 4:1 TBS volume:brain wet weight. Homogenate
was centrifuged for 30 min at 175,000  g in a 4°C TLA100.2 rotor on
Beckman TL 100 (resulting supernatant is termed TBS extract). Pellet
was resuspended in 2%SDSusing an 18 gauge needle, heated at 100°C for
10 min and spun at 21,130 g in an Eppendorf 5435 for 10 min (result-
ing supernatant is termed SDS extract). Pellet was washed twice more in
SDS, then incubated with 88% formic acid (FA) at room temperature for
2 h. Resulting supernatant (FA extract) was diluted 10 with water and
lyophilized.
Immunoprecipitation and Western blot for A. ISF and brain extracts
(except FA extract, which was lyophilized and directly reconstituted in
LDS sample buffer before loading) were immunoprecipitated with AW8
polyclonal antibody to A (1:100; gift from D. Walsh, Brigham and
Women’s Hospital) using Protein A (Sigma). For conventional SDS-
PAGE, a previously described protocol (Shankar et al., 2008) was fol-
lowed. Samples were electrophoresed using 12% Bis-Tris gel and MES
SDS running buffer (Invitrogen), transferred onto 0.2mnitrocellulose,
boiled, then blotted using monoclonal antibodies 6E10 (to A3–8; Cova-
nce) and 4G8, and visualized using the LiCor Odyssey Infrared Imaging
System. For bicine/urea-based SDS-PAGE, a previously described system
(Klafki et al., 1996) was modified. Briefly, 11% T/2.6% C 8M urea sepa-
ration gel was overlayered by 11% T/2.6% C 4M urea spacer gel and 4%
T/3.3% C comb gel. Gels were run at 12 mA for 1 h, then 34W for 3.8 h.
Proteins were transferred to PVDFmembranes, boiled then blotted with
6E10 with congo red, and detected using HRP and ECL Plus WB Detec-
tion Reagent (GE Healthcare).
Immunohistochemistry of brain sections. J20 APP tg brains at ages 3, 12,
and 24 months were fixed with 10% formalin, paraffin-embedded, then
sectioned at 8 m thickness, as previously described (Lemere et al.,
2002). R1282 polyclonal antibody was used to stain A and the immu-
noreactivity was visualized using the Vector Elite horseradish–peroxi-
dase ABC kit (Vector Laboratories) with diaminobenzidine (Sigma) as
the chromogen.
APP Western blotting. Mouse brains of 3- and 24-month-old tg mice
and wt littermates were homogenized in 1% (v/v) Nonidet P-40 STEN
buffer (in mM: 150 NaCl, 50 Tris, 2 EDTA) using a Teflon Dounce ho-
mogenizer. Brain lysates were loaded onto 4–12% Bis-Tris gel, electro-
phoresed with MES SDS running buffer, transferred onto 0.2 m
nitrocellulose, then blotted with polyclonal antibody C7 (to full-length
APP and its C-terminal fragments) and anti--tubulin polyclonal anti-
body (Thermo Scientific).
Size-exclusion chromatography. TBS extracts (250 l) or synthetic A
(2 ng) were eluted at 0.5 ml/min from a Superdex 200 10/300GL column
(GE Healthcare) with 50 mM ammonium acetate, pH 8.5. Resulting 1 ml
fractions were lyophilized, reconstituted in LDS sample buffer, and
heated at 65°C for 10 min. Samples were subjected to WB using 3D6 (to
A1–5; a gift from Elan) and the LiCor Odyssey Infrared Imaging System
or ECL Plus WB Detection Reagent (GE Healthcare).
Compound E treatment. Compound E (3 mg/kg; Axxora) was injected
intraperitoneally to mice undergoing microdialysis. Half-lives were cal-
culated according to Cirrito et al. (2003).
Radioactivity assay. For ISF experiments, 3 l of 1 nM [125I]--amy-
loid(1–40) (PerkinElmer) were injected through a combination infusion
cannula and microdialysis probe (IBR-2; Bioanalytical Systems) at 0.2
l/min. ISF was collected hourly at 0.6 l/min, paused during the injec-
tion, then restarted 1 min after injection. For TBS extractions, 5 l of
[ 125I]--amyloid(1–40) were injected in paired mice (young and old).
Brains were harvested for TBS extract preparation 1.5 h postinjection.
125I levels were counted using a LS6500multipurpose scintillation coun-
ter (8 min counts).
Clear native PAGE and subsequent denaturation for SDS-PAGE. TBS
extracts were prepared from homogenized brains of 24-month-old tg
mice and wt littermates, then subjected to non-denaturing clear native
PAGE, which separates proteins with isoelectric point 7 based on their
intrinsic charge (Wittig and Scha¨gger, 2005). Briefly, samples were electro-
phoresed using native PAGE 4–16%Bis-Tris gel (Invitrogen)with Bis-Tris-
HCl, pH 7.0, as anode and Tricine Bis-Tris, pH 7.0, as cathode buffers.
Proteins were then transferred onto 0.2 m PVDF (Millipore), boiled and
blotted forAusingmonoclonal antibodies 2G3 and21F12 (toA33–40 and
A33–42, respectively; gifts from Elan). For subsequent denaturation, we
excised two regions of the native PAGE gel following electrophoresis: the
300 kDa and the 80–230 kDa [based on NativeMark Unstained Protein
Standard (Invitrogen)]. The diced gels were heated at 100°C in denaturing
LDS sample buffer and supernatants were electrophoresed using 12% Bis-
Tris gel and MES SDS running buffer (Invitrogen) for Western blotting
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using monoclonal antibody 3D6 (to A1–5; gift from Elan). Proteins were
visualized using the Licor Odyssey Infrared Imaging System.
Statistical analysis. Data were analyzed using PRISM (Graphpad Soft-
ware) for one- or two-way ANOVA, followed by Bonferroni post hoc test
if means were significantly different by ANOVA, or Student’s t test, as
appropriate.
Results
Biochemical analysis of A peptides that remain soluble in
the brains of young, behaving hAPP transgenic mice
To examine the quality and quantity of A that remains soluble
and of low molecular weight in ISF in vivo (termed ISF A
herein), we used a microdialysis probe
with a 35 kDaMWCOmembrane in mice
expressing FAD-mutant human APP [J20
line (Mucke et al., 2000)].When we intra-
peritoneally injected Compound E, a
potent and brain-penetrant -secretase
inhibitor (Grimwood et al., 2005; Yan et
al., 2009), total ISF A captured inmicro-
dialysates fell rapidly (t1/2,2 h) to base-
line (Fig. 1a), showing thatmost of the ISF
A we sampled by microdialysis in young
mice represents newly synthesized APP
cleavage products. To capture the A spe-
cies that best reflect the physiological lev-
els, we performed microdialysis at a slow
perfusion rate of 0.2l/min for up to 72 h,
as this allows optimal exchange of free A
into the probe. ISF samples were immu-
noprecipitated with a polyclonal A anti-
serum (AW8), and the precipitates were
separated by denaturing PAGE and blot-
ted with pooledmonoclonal antibodies to
the N terminus (6E10) and midregion
(4G8) of A. The ISF Awas separated by
conventional SDS-PAGE into two species:
a 4 kDa monomer and a novel 5 kDa
species, which ran approximately half the
time as a band (Fig. 1b) and the other half
as a smear (Fig. 4a). We did not detect
dimers (which run at 6.5 kDa in these
gels; Fig. 1b) by IP/WB in the ISF of any of
the 40 mice we examined in this study,
regardless of age. In vitro (test tube) mi-
crodialysis of synthetic A40 showed that
our 35 kDa MWCO membrane allowed
passage of dimers; however, their diffu-
sion efficiency was low compared with
that of monomers (data not shown), sug-
gesting that the lack of dimers in the ISF
samples could be due to the detection
limit of the technique. Next, we analyzed
the mouse ISF by bicine/urea SDS-PAGE,
which electrophoretically separates A
peptides of different lengths (Klafki et al.,
1996). ISF A was resolved into three
principal bands comigrating with syn-
thetic A1–38, A1–40, and A1–42, plus a
fourth faint band comigratingwithA1–39
(Fig. 1c). Using a multiplex ELISA, we
confirmed the bicine/urea gel result that
A40 is the most abundant A in ISF (Fig.
1d). The A42 /A40 ratio in the ISF of
young, plaque-free J20 mice was calculated to be0.3. Using the
interpolated zero-flow method (Jacobson et al., 1985; Cirrito et
al., 2003), we estimated the total soluble A concentrations in
hippocampal ISF of 3-month-old tgmice to be1.2 nM (Fig. 1e).
ISF A decreases with age as A in brain parenchyma accrues
To elucidate how amyloid plaque development and maturation
affect the steady-state levels of brain ISFA, we sampled ISF from
the hippocampi of living J20 tg mice at three ages: preplaque (3
months), early plaque deposition (12 months), and abundant
andmature plaque deposition (24months) (Fig. 2a). The levels
Figure 1. ISF A obtained bymicrodialysis from behaving 3-month-old J20 hAPP tgmice. a, Rapid decline of ISF A (t1/2,2
h) upon acute-secretase inhibition in vivo in 3-month-old tg (vswt littermate)mice. ISF sampled hourly at 1l/min; Compound
E injected at time 0 h.b, c, ISF collected at 0.2l/minwere immunoprecipitatedwith AW8A antiserumand subjected to two
types of SDS-PAGE. b, Conventional SDS-PAGE separates ISF A into a 4 kDa [monomers (M)] and a 5 kDa A-
immunoreactive (lane 3) species. No dimers (D) were detected in ISF, but can be seen in the TBS-extract of a 24-month-old tg
mouse (lane 2) or synthetic (synth.) A (lane 1).WBwas performedwith 6E10 plus 4G8. c, Bicine/urea SDS-PAGE resolved ISF A
into three bands comigratingwith synthetic A1–38, A1–40, and A1–42, plus a fourth faint band corresponding to A1–39.WB
wasperformedwith6E10.d, Using6E10A triplex ELISA,wequantifiedAx–38, Ax–40, andAx–42 in ISF (meanSEM:635
70, 1937 311, and 592 58 pg/ml, respectively; n 7 mice). e, Interpolated zero-flow method (mean SEM; n 3–4
mice).
Figure 2. Amyloid plaques develop andmaturewith age in J20 APP tgmicewithout significant changes in full-length (FL) APP
or in its proteolytic processing by - or -secretases. a, Hippocampal sections from fixed J20 APP tg brain were paraffin-
embedded, then stained for A using R1282 polyclonal antibody. Three-month-old tg sections were virtually plaque-free,
whereas some plaques had formed by age 12 months. By 24 months, abundant diffuse and dense-core plaques populated the
hippocampus. b, Representative blot of brain lysates of 3- and 24-month-old tg mice and wt littermate loaded onto denaturing
SDS-PAGE, then blotted for full-length APP and its C-terminal fragments (CTFs) (WB was performed with polyclonal C7) or to
-tubulin (WB was performed with polyclonal tubulin-). c, Summary ratios of immunoreactive signals at 24- versus 3-month-
old tg mice, for full-length APP and C-terminal fragments normalized to the -tubulin signal. n 3 mice per group; signal
quantification by Licor Odyssey.
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of holoAPP and its C-terminal fragments
generated by - and -secretases were
constant over the 3- to 24-month ISF
sampling period (Fig. 2b), suggesting that
A production via APP proteolytic pro-
cessing does not change appreciably over
age. As quantified bymultiplex A ELISA,
all three A peptides measured in ISF
(Ax–38, Ax–40, and Ax–42) decreased
over time to levels that were significantly
reduced by 24 months (Fig. 3a–c shows
absolute values; Fig. 3d shows propor-
tional levels). As the individual peptides
fell to different degrees, the A42/A40 ra-
tio in the ISF shifted from 0.3 at 3 months
to 0.13 at 24 months. We estimated that
the total soluble A concentrations in
hippocampal ISF decreased from1.2 nM
in 3-month-old tg mice to0.5 nM in 24-
month-old tg mice (for concentrations of
individual A peptides in hippocampal
ISF of 3- and 24-month-old tg mice, see
Table 1). The similar percentage recovery
of microdialyzable A at 3 and 24months
(measured at five flow rates) indicates that
the age-dependent decrease in ISF A is
not due to technical issues with themicro-
dialysis system (Fig. 3e). We measured
analytes other than A present in the ISF
to see whether they are also altered with
age, in particular, lactate, pyruvate, and
glycerol. The ratio of lactate to pyruvate is
Figure 4. A in all pools of brainparenchymaaccruewithagewhile those that remaindiffusible in the ISFdeclines.a, Representative
IP/WBs of A species frombrains of the samemice right aftermicrodialysis, in four pools: ISF, TBS extracted (ext), SDS extracted, and FA
extracted.Allpools (exceptFAextracted,whichwas lyophilizedandstraight-loadedontothegel)were immunoprecipitatedwithAW8and
blottedwith6E10and4G8.Synthetic (synth.)A runalongsideforquantification.Perfusionbuffer(PB)andTBSwereimmunoprecipitated
as negative controls.b–e, Quantification of IP/WBs from21mice shows50%decrease in absolute values of ISF A between 3 and 12
months(notsignificantbyone-wayANOVAfollowedbyBonferroni test) (b),withasharprise inTBS- (c),SDS- (d),andFA-(e)extractedA
(picogramspermilligramswetbrain tissue). f,g,Ratiosof ISF toTBS-solubleA (f )or to totalparenchymalA (g) calculated foreachmouseand
shownasmeanratioSEM;n7micepergroup.AquantifiedbyLicorOdysseyimagingandanalyzedbyone-wayANOVAandBonferronitest:
**p0.01and***p0.001versus3months; #p0.05and ##p0.01versus12months.D,Dimers;M,monomers.
Figure 3. Levels of soluble ISF A35 kDa in the brain fall with age.a–d, ISFwas sampled from the hippocampi of 3- (preplaque), 12- (early plaque deposition), and 24-month old (abundant,
mature plaques) J20 tg mice. Using A triplex ELISAs, we found that Ax–38 (a), Ax–40 (b), and Ax–42 (c) all decreased with age (means SEM; n 7, 4, 7 mice at 3, 12, and 24 months,
respectively). One-way ANOVA, followed by Bonferroni test: *p 0.05, **p 0.01, and ***p 0.001 versus 3months values; #p 0.05 versus 12months values. d, Proportional levels of A38,
A40, and A42, where each peptide was normalized to its level at 3 months. A42 declined the most (80% by 24months vs 3 months). ***p 0.0001 by two-way ANOVAwith age as a variant.
e, At 0.2l/min, the perfusion rate used to collect all ISF samples in Figures 3 and 4, we obtained comparable percentage recoveries ofmicrodialyzable A in the two extreme ages (63 3% in
3-month-old tgmice and662% in24-month-old tgmice,means SEM;n3–4mice). f,g, Ratios of lactate topyruvate (f ) andglycerol (g) levels in the ISFmicrodialysateswerenot altered
with age (means SEM; n 3–8 mice).
Table 1. Theoretical concentrations of microdialyzable ISF A in vivo at zero-flow rate
A38 (pg/ml) A40 (pg/ml) A42 (pg/ml) A42:A40
3 mo 24 mo 3 mo 24 mo 3 mo 24 mo 3 mo 24 mo
ISF A	 of J20 tg mice 930 658 2975 1231 880 166 0.30 0.13
Concentrations of endogenous hippocampal ISF A38 , A40 , and A42 were calculated by extrapolating the curves generated from the interpolated zero-flow method to zero PR (Fig. 5). Ratios of A42 /A40 in the ISF of 3- and
24-month-old tg mice were calculated to be0.30 and 0.13, respectively, reflecting a higher drop of A42 versus A40 in 24-month-old tg mice.
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an established marker of the redox state of cells; glycerol is an
integral component of cellular membranes, and changes in its
level can reflect degradation ofmembranes (Ungerstedt and Ros-
tami, 2004). Neither the lactate-to-pyruvate ratio nor the level of
glycerol in ISF changed significantly during our 3–24 months
sampling period (Fig. 3f,g), suggesting that the decrease in A is
not associated with altered intermediary metabolism or pertur-
bation of cell membrane integrity.
Next, we sought to identify the pathophysiological relation-
ship between ISF A and the accrual of increasingly less soluble
A in brain parenchyma during the development of AD-type
neuropathology. Using a sensitive IP/WB method (Walsh et al.,
2002; Shankar et al., 2008), we compared the quantity and type of
A in ISF obtained in vivowith three pools of brain parenchymal
A isolated from the same mice right after the dialysis: TBS ex-
tract (traditionally defined as the soluble A fraction), detergent
(SDS) extract (aggregated and membrane-associated A), and
FA extract [A from highly insoluble deposits, including plaque
cores (Masters et al., 1985; Selkoe et al., 1986)]. As reported pre-
viously for the J20 line and other APP tg mice (Johnson-Wood et
al., 1997; Hsia et al., 1999; Mucke et al., 2000; Kawarabayashi et
al., 2001; Shankar et al., 2009), we observed an age-dependent rise
in levels of all three pools of parenchymal A (Fig. 4a). Both the
SDS and FA extracts rose sharply with age (Fig. 4a,d-e). A in the
TBS extract did not rise substantially until 24 months, an age at
which we regularly observed SDS-stable dimers in this fraction
(Fig. 4a,c). In contrast to these age-dependent rises in parenchy-
mal A, there was a decline in the ISF. We observed a 50% de-
crease in total absolute ISF A levels between 3 and 12 months
(Fig. 4b), before there was an appreciable rise in the TBS extract
(Fig. 4c).We next analyzed the values in eachmouse to determine
what portion of its TBS-soluble A remains dialyzable in vivo,
and observed a fivefold decline in the ISF/TBS ratio between 3
and 12 months (Fig. 4f). When normalized to total brain paren-
chymal A, the relative ISF level declined even more (Fig. 4g).
Thus, all A pools in brain parenchyma
rise with age, while that which remains
diffusible in ISF in vivo sharply declines.
Altered dynamics of soluble A in
plaque-rich versus plaque-free mice
Sampling the ISF at slower perfusion rates
(which allows formore efficient dialysis of
ISF solutes) revealed age-dependent changes
in ISFA (Fig. 5). Inparticular, thismethod
revealed significantly decreased diffusion of
endogenous A40 and A42 into themicro-
dialysis probe in 24-month-old compared
with 3-month-old mice. To better under-
stand the basis for this marked decrease in
recovery of diffusible ISFA in the presence
of abundant plaques, we approximated the
fate of newly secreted A molecules by
exogenously administering radiolabeled
solubleA.We acutely injected soluble syn-
thetic [125I]A1–40 at a physiological con-
centration (1 nM), via a small cannula
attached to themicrodialysis probe, into the
hippocampal ISF of either age 3–7 months
(plaque-free)orage24–27months (plaque-
rich). We then measured the ability to re-
cover the radiolabeled peptide from the ISF
by microdialysis. From the ISF of the
plaque-richmice,we recoveredonly45%of the injectedpeptide that
was recovered from the ISF of plaque-free mice (p 0.0001) (Fig.
6a). The amounts of the injected [125I]A thatwere recovered at the
two ages correlatedwell with the respective endogenousA concen-
trations in the ISF before injection: the [125I]A levels observed in
the first hour and the endogenous A levels just before injection
were both high in youngmice and low in oldmice (Fig. 6b), indicat-
ing that the acutely injected radiopeptide achieves a similar equilib-
riumas the endogenousAhas at steady state.Wehypothesized that
in plaque-rich mice, the acutely administered monomer is more
readily incorporated into their abundantAdeposits and thus is less
recoverable in the ISF. To address this idea, we quantified the radio-
activity retained in the TBS extracts of brain.We saw a substantially
Figure 5. Microdialysis at slower perfusion rates reveals age-dependent changes in ISF A.
ISF were collected from hippocampi of 3- (plaque-free) and 24- (plaque-rich) month-old tg
mice while varying the PR. Samples were then quantified using 6E10 A triplex ELISA. a– c, At
PR 1l/min, no age-dependent changes in any of the three peptides were detectable; how-
ever, at slow PRs (especially 0.2 l/min), significant differences were noted, particularly in
A40 and A42. d, Sum of the three A peptides measured (total A). Values are means
SEM, n 3–7 mice; p values by two-way ANOVA and Bonferroni test.
Figure 6. Dynamic shift in the in vivo economy of A once plaques develop. a– c, Soluble synthetic [ 125I]A1–40 at a physio-
logical concentration (1 nM) was injected intrahippocampally via a small cannula on the microdialysis probe in awake, behaving
mice at ages 3–7 (plaque-free) or 24–27 (plaque-rich)months, and radioactivitywas recovered in the ISF bymicrodialysis (a) and
from the TBS extracts of the brains (b). Means normalized to amounts in the plaque-freemice (100%) SEM; n 3–4mice per
group; p values are one-tailed t tests versus 3–7 months. c, Amount of [ 125I]A recovered in the first hour of injection plotted
versus the endogenous A levels sampled from samemice before injection.d–f, ISF A42 isminimally affected by Compound E in
plaque-richmice. d, Representative graph of hourly ISF A levels after Compound E injection (0 h) into 24-month-old plaque-rich
mice while collecting their brain ISF at 0.6 l/min. Levels were normalized to levels of each A species before injection. e,
Quantification of the individual ISF A peptides in 24-month-old plaque-rich mice for the first 5 h postinjection (means SEM,
n 3mice; p value is by one-way ANOVA). f, Hourly ISF A levels after Compound E injection (0 h) in a 3-month-old plaque-free
tg mouse.
Hong et al. • ISF A Levels Before and After Plaque Formation J. Neurosci., November 2, 2011 • 31(44):15861–15869 • 15865
higher amount of the fresh, exogenous ra-
diopeptide retained in the TBS extracts of
the older mice (Fig. 6c). In the short time
frame we conducted these analyses (i.e., the
first 90 min after administration), we did
not detect significant levels of radioactivity
in the SDS andFA fractions. Together, these
results suggest that in plaque-burdened
mice, newly generated soluble A released
into the ISF readily accrues onto parenchy-
mal deposits, accounting for its lower
steady-state level in the ISF.
The level of ISF A42 in plaque-rich
mice is minimally affected by acute
-secretase inhibition
To assess whether the ISF A we mea-
sured in plaque-rich older mice also rep-
resents recent APP cleavage products, as
we had determined in young mice (Fig.
1a), we acutely inhibited -secretase in
vivowith Compound E. There was a rapid
decline of A38 and A40 (60% fall in
the first 3 h; t1/2, 1.9 h and 2.3 h, re-
spectively), whereas A42 declined signif-
icantly less (20% fall) (Fig. 6d,e). In
contrast, all three peptides fell together in
young plaque-free mice during the first
5 h after shutting down new production
with Compound E (Fig. 6f). As A42 is the
species reported to accumulate much
more into plaques than the other, more
abundantly generatedApeptides in both
AD patients and APP mice (Iwatsubo et
al., 1994; Johnson-Wood et al., 1997),
these results suggest that most of the sol-
uble A42 peptide that populates the ISF
pool in plaque-rich mice is not derived
primarily from new A biosynthesis but
rather from the large reservoir of less sol-
uble A42 in the brain parenchyma. The
results also indicate that acute -secretase
inhibition is less effective in loweringA42
in plaque-rich brains.
Saline-extractable A of brain
parenchyma in its native form appears
to exist principally in assemblies>500
kDa
Bicine/urea SDS-PAGE gels showed that
the A peptide distribution differed be-
tween the ISF and TBS-extracted pools at
all ages (Fig. 7a). Even at age 3 months, when the brain has vir-
tually no plaques, A40 was the primary A species in ISF, while,
in the TBS-extracted pool, A42 was already the more abundant
peptide at steady state, despite the fact that it is generated inmuch
lower amounts than A40 (Fig. 7a). Accordingly, the A42/A40
ratio differed markedly between the ISF (low ratio) and TBS ex-
tract (very high ratio) (Fig. 7b). This stark difference led us to
question the general assumption that the brain A pool that
comes into solution upon mechanical homogenization in physi-
ological buffers represents the truly soluble pool (McLean et al.,
1999; Walsh and Selkoe, 2004; Shankar et al., 2009). We per-
formed non-denaturing SEC on the TBS extract and subjected
the resultant SEC fractions to SDS-PAGE for WB analysis. Sur-
prisingly, most A in the TBS extracts of plaque-free (3 months
tg)mice eluted in the void volume of a Superdex 200 SEC column
[suggesting a molecular weight (MW)500 kDa], and this ma-
terial ran principally as monomers when electrophoresed on a
denaturing gel (Fig. 7c, fractions 6 and 7). The SEC elution pro-
files of TBS extracts from 3- and 24-month-old tg mice were
similar and differed sharply from that of synthetic A40 peptide
alone (Fig. 7c). In accordance with this, A in TBS extracts from
24-month-old tg mice ran as an aggregated, high MW complex
Figure 7. Saline brain extracts of tg mouse exists principally in assemblies500 kDa in native form. a, Bicine/urea SDS-PAGE
shows the principal Apeptides present and their relative expression levels in ISF and TBS extracts of 3-, 12-, and 24-month-old tg
mice. IP was performed with AW8; WB was performed with 6E10. b, Quantification (by ImageJ software) of A42/A40 ratios in
plaque-free 3-month-old tg mice (p value by one-tailed t test; n 3 each). c, Non-denaturing SEC of TBS extracts (ext) of 3- and
24-month-old tg mice performed on a Superdex 200 SEC column followed by SDS-PAGE of each SEC fraction. Synthetic (synth.)
A40 runon the sameSEC column for comparison.WBwasperformedwith3D6.d, TBS extracts froma24-month-old tgmouse and
its wt littermate subjected to clear native PAGE and blotted for A. WB was performed with 2G3 plus 21F12. e, Excision of the
300 kDa region and subsequent electrophoresis by denaturing SDS-PAGE showed that this high MWmaterial is disassembled
into lowMW SDS-stable A species. WB was performed with 3D6. T, Trimers; D, dimers; M, monomers; MWM, MWmarker.
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on a clear native PAGE gel, whereas synthetic A40 ran close to
the dye front (Fig. 7d). Excision of the 300 kDa region and
subsequent denaturation in LDS sample buffer yielded lower
MW A species, including monomers (Fig. 7e).
Discussion
Although factors other than A dyshomeostasis contribute im-
portantly to the pathogenesis of AD (Pimplikar et al., 2010),most
potentially disease-modifying treatments currently under devel-
opment are focused on decreasing or neutralizing this neurotoxic
peptide. Moreover, a reduced CSF level of A42 in subjects with
incipient or very early AD is one of themost promising biomark-
ers. Despite this therapeutic and diagnostic focus, we still lack
insight into the in vivo economy of soluble A in the brain as
AD-type pathology forms. Here, we used the powerful method of
brain microdialysis in awake, behaving hAPP transgenic mice to
gain understanding of the dynamics of the most soluble forms of
A in the hippocampus before and during
the process of A plaque formation. Our
results show that A peptides, which re-
main soluble and of lowmolecular weight
in the interstitial fluid in vivo, decrease
significantly—both absolutely (Figs. 3–5,
7a) and especially in relation to the solu-
ble A extractable from brainmembranes
(Fig. 4d)—as plaques accumulate. A42
decreases themost among the threemajor
A peptides in the ISF; in agreement with
this, A42 rises the most in the less soluble
A pools in the brain parenchyma (Figs.
3, 7a), keeping with its documented pri-
mary role in oligomerization and plaque
formation. Figure 8 provides summaries
of the temporal changes documented in
this study.
Of special clinical relevance is that our
discovery of an age-dependent decrease in
ISF A42 may be analogous to the widely
documented selective decrease in soluble
A42 in human (AD) CSF (Motter et al.,
1995). In humans, CSF levels of A42 ap-
pear to relate inversely to amyloid plaque
burden, degree of brain atrophy, and se-
verity of cognitive deficits in humans
(Motter et al., 1995; Fagan et al., 2009;
Shaw et al., 2009). Our dynamic studies of
the change in endogenous ISF A and of
the fate of radiolabeled A before versus
after plaque initiation offer strong evi-
dence from controlled animal experi-
ments for the hypothesis that soluble A42
in humans falls in the CSF because it is
sequestered into increasingly insoluble
parenchymal deposits as AD develops.
What are the driving forces leading to
the sharp decline of diffusible A species
as AD-like pathology progresses with age?
The constant levels of both full-length
APP and the C-terminal fragments gener-
ated by - and -secretases suggest that
the fall we observe is not due to a decrease
of cellular production of A. We also saw
no evidence for a perturbation of cell
membrane integrity, a change in an indi-
cator of intermediarymetabolism, or altered spontaneous behav-
ior (eating, exploring, grooming, etc.) in the mice, arguing
against general cytotoxicity or cell death as an explanation for the
drop. Thus, we obtained no evidence that decreased neuronal
activity or decreased A production explains the drop in soluble
ISF A as mice accrue amyloid deposits. Rather, the decrease in
ISF A occurred simultaneously with rises of insoluble A in the
SDS- and FA-extractable pools (Figs. 3, 4). Furthermore, the dis-
tinct dispositions of soluble radiolabeled A injected at physio-
logical concentrations directly into the ISF in plaque-free versus
plaque-rich animals provide insight into a shift in A economy:
in plaque-richmice, A becomes rapidly less diffusible andmore
associated with the loosely membrane-bound (TBS-extractable)
pool (Fig. 6). This dynamic shift leads us to hypothesize that once
an A peptide binds to membranes and/or plaques, it is seques-
tered there and becomes less diffusible, at least temporarily, lead-
Figure8. Summaryof the temporal changes in the fourAbrainpools.a, Decreaseswithage in all three in vivo ISFApeptides
measured by 6E10 A triplex sandwich ELISA (for details, see Fig. 3).b, The fold-decreasemeasured by ELISA (significant between
ages3and24monthsby two-wayANOVA; see Fig. 2) is comparable to the fold-decreasemeasuredby IP/WB(though the latterwas
not significant by one-way ANOVA; for details, see Fig. 4). The total amountmeasured by IP/WB analysismethodwas only30%
of the total amount measured by ELISA. c, IP/WB analysis of A in brain tissue. By24 months, there was a steep increase in
insoluble (SDS- and FA-extracted) A. The TBS-extracted A from the samemice did not rise until 24 months and then only very
slightly. Values are means SEM from Figures 3 and 4.
Figure 9. A hypothetical model of A in vivo dynamics before versus after plaque formation based on data herein. Several
factors contribute to steady-state A levels in brain ISF. There is a constant supply of A in the ISF pool generated by new APP
processing (A40A38A42A39), and this generation appears to change littlewith age. ISF A canbeproteolytically
degraded, cleared locally by glia and/or transported across the blood brain barrier (BBB). Soluble A starts aggregating at an early
age in brain parenchyma, as evidenced by the500 kDa TBS-extractable pool as well as an SDS-extractable pool in 3-month-old
plaque-free mice. The most abundant pools in a plaque-free brain are the ISF pool and the SDS-extractable pool. In a plaque-rich
brain, however, equilibrium between pools is greatly altered by the overwhelming amount of aggregated A, which act as a sink,
thereby diminishing the steady-state ISF pool. Plaques may also act as a contributor to the ISF pool, where A42, the most
abundant peptide in plaques (and also themost decreased in the ISF) diffuses back into the ISF. HMW, HighMW (i.e.,500 kDa).
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ing to decreased recovery during microdialysis, consistent with a
report of lengthened A clearance time in old versus young APP
transgenic mice (Cirrito et al., 2003).
Indirect evidence for a converse pathway suggests that such
membrane association is not irreversible. Our finding that upon
acute -secretase inhibition there was significantly less fall in ISF,
specifically of A42 (which is much more abundant in plaques),
suggests that plaques contribute to a dynamic equilibrium be-
tween soluble and insoluble A42 pools in the brain and thus help
regulate the steady state of ISF A in aged mice (for a model, see
Fig. 9). This concept is consistent with evidence that amyloid
plaques in APP transgenic mice appear to act as a local reservoir
of loosely associated A that can diffuse from plaques and pop-
ulate a halo of oligomeric and monomeric A immediately sur-
rounding the amyloid core (Spires et al., 2005; Koffie et al., 2009).
It will be interesting to see whether acute alteration of one partic-
ular A pool (e.g., via agents such as antibodies that can selec-
tively bind aggregated A or agents that only sequester the fully
soluble ISF pool) will have transient or lasting effects on the equi-
librium maintained among the A pools.
A in aqueous extracts of homogenized cerebral cortex has
been termed by our group and others as the “soluble A” pool
and is thought to be derived from ISF and cytosol, not necessarily
from particulates such as amyloid deposits (Gravina et al., 1995;
Lue et al., 1999; McLean et al., 1999; Walsh and Selkoe, 2004;
Shankar et al., 2009); the rise in this pool was thought to reflect a
rise in diffusible A in vivo. However, we show here that A
peptides in aqueous parenchymal extracts differ significantly in
quality and quantity from those that remain of lowMWin the ISF
pool. Furthermore, using non-denaturing SEC and native gels,
we show that much native A in the TBS extracts of APP trans-
genicmouse brains, even at a preplaque age of 3months, exists in
assemblies 500 kDa, extending similar data on the aqueous
extracts of AD brains (Shankar et al., 2008). Thus, aqueous ex-
tracts of A may principally reflect aggregated A peptides
bound to cellmembranes (in youngmice) and tomembranes and
plaques (in older mice) but which remain water-extractable.
Given this new understanding that aqueous extracts of brain
may not reflect the truly diffusible A species in vivo, it will be
important to examine the nature of synaptotoxicity in the differ-
ent A pools, including the ISF pool and the TBS-extracted pool,
which is currently thought to principally contain the toxic oligo-
meric species. Interestingly, we have not detected SDS-stable
dimers in any of our ISF microdialysates to date, which could be
due in part to the limits of detection. Using a test tube model of
our microdialysis technique, we found that synthetic A dimers
(8 kDa) crossed over the 35 kDaMWCOmembrane; however,
the diffusion efficiency of dimers was poor comparedwith that of
monomers (data not shown). Therefore, we cannot exclude the
existence of low levels of soluble dimers in the ISF of hAPP trans-
genic mice. Our results may instead suggest that soluble dimers
and other oligomers do not actually exist per se in the most dif-
fusible brain pool (ISF); rather, newly formed oligomers (with
their exposed hydrophobic amino acids) may distribute quickly
onto hydrophobic surfaces (cell membranes and/or amyloid
deposits).
As regards the implications of our findings for the pathophys-
iology of AD, it will be important in future studies to attempt to
detect any bioactivity of the ISF A pool at the different plaque
stages of APP transgenicmice.Whereas the ISF of young, plaque-
free mice acts as a reservoir mainly for the acute cellular produc-
tion of A, ISF in plaque-rich mice seems to be a reservoir for
both new A production and A that diffuses from membrane-
and plaque-bound deposits (as evidenced by the finding that ISF
A42 levels do not fall significantly upon acute inhibition of
-secretase). Whether the A42 that comes off of parenchymal
deposits into the ISF is pathogenically important (comparedwith
A in the ISF of plaque-free brains) will be important to
determine.
In conclusion, these dynamic analyses provide unique insights
into the generation of first fully soluble and then increasingly less
solubleA species during age-related accrual of AD-type amyloid
deposits in living animals. Based on the usefulness of these pre-
clinical data, we suggest a provocative approach toward poten-
tially extending such studies to humans. Patients with normal
pressure hydrocephalus (NPH), which is typified by a clinical
triad of subacutely developing dementia, incontinence, and gait
ataxia (Relkin et al., 2005; Shprecher et al., 2008), are frequently
offered a neurosurgical procedure by which a ventriculoperito-
neal shunt is inserted to chronically drain the excess ventricular
CSF to the peritoneal cavity and thus potentially improve the
patients’ NPH symptoms. Several studies of simultaneously ob-
tained cortical biopsies have shown that some or many such
shunted patients show amyloid plaques and neurofibrillary tan-
gles indistinguishable from those in typical AD patients (Del Bi-
gio et al., 1997; Bech et al., 1999; Golomb et al., 2000; Hamilton et
al., 2010). This co-occurrence suggests that obtaining institu-
tional review board approval to perform a brief (12–24 h) place-
ment of a microdialysis probe at the time of an NPH shunt
placement could enable in vivo analysis of ISF A peptides in
humans with varying degrees of A deposition. We propose that
such controlled clinical research studies in appropriate patients
be considered to obtain direct information about the economy of
themost soluble species of brainA (those in ISF) as a function of
the level of cerebral -amyloidosis in humans.
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